Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pascal Machiels

Showing results (11-20 of 172) with videos related to

Pageof 18
Sort By:
Cancer Treatment Reviews|April 2, 2015
Molecular biology and targeted therapies for urothelial carcinomaEmmanuel Seront, Jean-Pascal Machiels
Journal of Oncology|January 15, 2010
Antivascular therapy for epithelial ovarian cancerFrancois P Duhoux, Jean-Pascal Machiels
Current Opinion in Oncology|April 16, 2019
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neckGabrielle van Caloen, Jean-Pascal Machiels
Urologia Internationalis|December 23, 2014
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent maleMarco Gizzi, Selda Aydin, Jean-Pascal Machiels
Cancers|December 10, 2021
Vaccine-Based Immunotherapy for Head and Neck CancersSimon Beyaert, Jean-Pascal Machiels, Sandra Schmitz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
HER2 and HER3 in HPV+ and HPV- HNSCC--LetterJean-Pascal Machiels, Rachel Galot, Sandra Schmitz
Oral Oncology|May 26, 2019
May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?Paolo Bossi, Emmanuel Seront, Jean Pascal Machiels
Cancer Treatment Reviews|February 2, 2016
Window of opportunity studies: Do they fulfil our expectations?Sandra Schmitz, François Duhoux, Jean-Pascal Machiels
Cancer Biology & Therapy|September 9, 2017
Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neckMariama El Baroudi, Jean-Pascal Machiels, Sandra Schmitz
Current Opinion in Oncology|April 14, 2012
Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapyDiocésio A P de Andrade, Jean-Pascal Machiels
Pageof 18

Showing results (11-20 of 172) with videos related to

Sort By:
Pageof 18
Cancer Treatment Reviews|April 2, 2015
Molecular biology and targeted therapies for urothelial carcinomaEmmanuel Seront, Jean-Pascal Machiels
Journal of Oncology|January 15, 2010
Antivascular therapy for epithelial ovarian cancerFrancois P Duhoux, Jean-Pascal Machiels
Current Opinion in Oncology|April 16, 2019
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neckGabrielle van Caloen, Jean-Pascal Machiels
Urologia Internationalis|December 23, 2014
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent maleMarco Gizzi, Selda Aydin, Jean-Pascal Machiels
Cancers|December 10, 2021
Vaccine-Based Immunotherapy for Head and Neck CancersSimon Beyaert, Jean-Pascal Machiels, Sandra Schmitz
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
HER2 and HER3 in HPV+ and HPV- HNSCC--LetterJean-Pascal Machiels, Rachel Galot, Sandra Schmitz
Oral Oncology|May 26, 2019
May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?Paolo Bossi, Emmanuel Seront, Jean Pascal Machiels
Cancer Treatment Reviews|February 2, 2016
Window of opportunity studies: Do they fulfil our expectations?Sandra Schmitz, François Duhoux, Jean-Pascal Machiels
Cancer Biology & Therapy|September 9, 2017
Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neckMariama El Baroudi, Jean-Pascal Machiels, Sandra Schmitz
Current Opinion in Oncology|April 14, 2012
Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapyDiocésio A P de Andrade, Jean-Pascal Machiels
Pageof 18